Saturday, May 5, 2012

Should the FDA Approve More Drugs after Phase II?


Another article in Forbes. Well, why not? Very sober arguments are summarized in the video:



But the changes proposed will simplify the life for smaller companies which is not so good for Big Pharma who literally monopolized phase III trials market. (We have this Feuerstein-Ratain rule which explains that almost only Big Pharma can drive the drug candidate through very costly phase III study). Only politicians can help here, FDA and Big Pharma are absolutely not motivated to make any changes in the rules. But on the other hand the politicians are constantly and massively lobbying by Big Pharma. Why they should be interested? .. Well, I am afraid that nothing will be changed. Unfortunately...

No comments:

Post a Comment